

CITATION REPORT

List of articles citing

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease

DOI: 10.1164/rccm.200702-326oc

American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1026-34.

Source: <https://exaly.com/paper-pdf/41662219/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
381	Subacute necrotizing encephalopathy: oxidative phosphorylation defects and the ATPase 6 point mutation. 1992 , 42, 2168-74		154
380	Pulmonary complications: one of the most challenging complications of systemic sclerosis. 2009 , 48 Suppl 3, iii40-4		54
379	Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 952-3	10.2	24
378	Sklerodermie syst�mische: Etat des lieux en 2008. 2008 , 75, 918-924		
377	Lungenbeteiligung bei Sklerodermie. 2008 , 5, 299-307		1
376	Systemic sclerosis: an update in 2008. 2008 , 75, 650-5		48
375	Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. <i>Arthritis Research and Therapy</i> , 2008 , 10, R124	5.7	105
374	Pneumopathies interstitielles diffuses (PID) associ�es aux connectivites. 2008 , 25, 69-76		
373	Current approaches to the management of early active diffuse scleroderma skin disease. <i>Rheumatic Disease Clinics of North America</i> , 2008 , 34, 161-79; viii	2.4	17
372	[New clinical features in scleroderma]. 2008 , 4 Suppl 1, 45-9		1
371	Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. 2008 , 28, 926-37		20
370	Pulmonary function tests. 2008 , 47 Suppl 5, v65-7		51
369	Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive. 2008 , 31, 1148-9		11
368	Interstitial lung disease in systemic sclerosis: a simple staging system. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1248-54	10.2	685
367	Trial design: how must we move ahead?. 2008 , 47 Suppl 5, v57-8		2
366	Stem cell transplantation: a treatment option for severe systemic sclerosis?. 2008 , 67 Suppl 3, iii35-8		17
365	Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1292-3; author reply 1293	10.2	1

364	Scleroderma lung disease: "if you don't know where you are going, any road will take you there". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1178-9	10.2	10
363	Update in diffuse parenchymal lung disease 2007. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 580-4	10.2	10
362	Diagnostik und Therapie der Systemsklerose. 2008 , 33, 90-101		
361	Therapies for interstitial lung disease: past, present and future. 2008 , 2, 319-38		45
360	Prognostic Significance of Bronchoalveolar Lavage Cellular Analysis in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1293-1293	10.2	0
359	The EULAR Scleroderma Trials and Research Group (EUSTAR): an international framework for accelerating scleroderma research. 2008 , 20, 703-6		8
358	Current world literature. 2008 , 20, 729-35		
357	Bibliography. Current world literature. Disorders of pulmonary circulation. 2008 , 14, 493-500		
356	Scleroderma lung disease: evolving understanding in light of newer studies. 2008 , 20, 686-91		30
355	Interstitial lung disease: trials and tribulations. 2008 , 14, 427-33		7
354	Treatment of systemic sclerosis: potential role for stem cell transplantation. 2009 , 2, 1-9		1
353	Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis. 2009 , 5, 35-43		1
352	Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. <i>American Journal of the Medical Sciences</i> , 2009 , 337, 329-35	2.2	78
351	Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. 2009 , 136, 1333-1340		104
350	Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis. 2009 , 5, 225-8		2
349	[Lung impairment in systemic sclerosis]. 2009 , 63, 497-507		2
348	Update in diffuse parenchymal lung disease 2008. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 439-44	10.2	11
347	Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. 2009 , 36, 1460-3		27

346	Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. 2009 , 36, 2737-43		90
345	Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. 2009 , 33, 882-96		116
344	Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. 2009 , 28, 391-5		34
343	Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report. 2009 , 28 Suppl 1, S31-4		1
342	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. 2009 , 11, 111-9		40
341	Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. 2010 , 40, 494-502		6
340	[Systemic sclerosis. Objectives for the treatment]. 2009 , 68, 37-43		
339	[Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?]. 2009 , 30, 955-62		1
338	[Dyspnea upon exertion in systemic scleroderma: from symptom to etiological diagnosis]. <i>Presse Medicale</i> , 2009 , 38, 911-26	2.2	6
337	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon. 2009 , 77-95		
336	Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario. <i>Arthritis Research and Therapy</i> , 2009 , 11, 103	5.7	7
335	Pneumopathies interstitielles diffuses. <i>Revue Des Maladies Respiratoires Actualites</i> , 2009 , 1, S116-S129		o
334	High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. 2009 , 12, 239-42		23
333	Disease-modifying treatment in systemic sclerosis: current status. 2009 , 21, 636-41		35
332	Mycophenolate in the Treatment of Scleroderma-Associated Interstitial Lung Disease and Other Collagen Vascular Disease-Related Interstitial Lung Disease. 2009 , 16, 194-198		
331	Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. 2009 , 16, 74-80		10
330	Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease. 2009 , 2009, 46-47		
329	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. 2010 , 6, 138-144		21

328	Sclérodémie systémique. 2010 , 5, 1-14	
327	Acute exacerbations of interstitial lung diseases. 2010 , 16, 480-6	23
326	Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. 2010 , 29, 1167-8	53
325	Evidence-based management of rapidly progressing systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 387-400	53 52
324	Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. 2010 , 62, 2101-8	84
323	Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. 2010 , 37, 323-9	7
322	Strategies for treating idiopathic pulmonary fibrosis. 2010 , 9, 129-40	180
321	Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study. 2010 , 7, 85-9	
320	Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. 2010 , 35, 112-7	54
319	Molecular Basis of Pulmonary Disease. 2010 ,	3
318	Update on diffuse parenchymal lung disease. 2010 , 19, 97-108	8
317	Immunotherapy of systemic sclerosis. 2010 , 2, 863-78	35
316	Targeted therapy for systemic sclerosis: how close are we?. 2010 , 6, 269-78	18
315	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 2010 , 39, 155-9	2
314	New pharmacological strategies for the treatment of pulmonary fibrosis. 2010 , 4, 353-66	15
313	Pulmonary manifestations of scleroderma and mixed connective tissue disease. 2010 , 31, 433-49	26
312	Pharmacotherapy of systemic sclerosis. 2010 , 11, 789-806	14
311	Esclerodermia sistémica. 2010 , 44, 1-15	

310	Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. 2010 , 49, 271-80		281
309	Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. <i>Arthritis Research and Therapy</i> , 2010 , 12, 213	5.7	95
308	Interstitial Lung Disease in Children Older Than 2 Years. 2010 , 23, 33-41		25
307	Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. <i>Modern Rheumatology</i> , 2011 , 21, 296-301	3.3	18
306	Efficacy of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis. 2011 , 47, 239-245		1
305	Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. 2011 , 8, 53-82		112
304	Autoimmune Diseases. 2011 ,		1
303	Correlation between pretreatment or follow-up CT findings and therapeutic effect of autologous peripheral blood stem cell transplantation for interstitial pneumonia associated with systemic sclerosis. 2011 , 79, e74-9		6
302	Lung involvement in systemic sclerosis. <i>Presse Medicale</i> , 2011 , 40, e3-e17	2.2	21
301	Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. 2011 , 378, 498-506		330
300	Lung. 2011 , 847-864		
299	Autologous hematopoietic stem cell transplantation for systemic sclerosis. 2011 , 6, 16-28		11
298	Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. 2011 , 23, 519-29		13
297	Management of interstitial lung disease in systemic sclerosis. 2011 , 6, 503-515		
296	Scleroderma: the need for extreme remedies. <i>American Journal of the Medical Sciences</i> , 2011 , 342, 416-21.2		3
295	Diagnosis and management of diffuse lung disease in children. 2011 , 12, 238-42		27
294	Efficacy of cyclophosphamide in the treatment of interstitial lung disease associated with systemic sclerosis. 2011 , 47, 239-45		8
293	Interstitial lung disease in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011 , 10, 248-55	13.6	87

292	Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. 2011 , 141, 293-303	17
291	A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. 2011 , 30, 223-9	27
290	Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. 2011 , 30, 1393-8	54
289	Scleroderma lung disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2011 , 40, 104-16	12.3 30
288	Cyclophosphamide responsive interstitial lung disease in "overlap syndrome": a clinical pathology conference held by the division of rheumatology at the hospital for special surgery. 2011 , 7, 99-105	
287	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. 2011 , 63, 2797-808	83
286	Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. 2011 , 5, 299-304	22
285	Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. 2011 , 38, 1355-60	79
284	Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons. 2011 , 6, 219-230	3
283	Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. 2011 , 38, 1925-30	23
282	Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. 2011 , 38, 2186-92	17
281	Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. 2012 , 2012, 143637	44
280	Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. 2012 , 67, 157-63	37
279	Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: "it is a matter of the heart". 2012 , 39, 206-9	19
278	Mycophenolate mofetil (MMF) for the treatment of connective tissue disease-associated interstitial lung disease (ILD). 2012 ,	
277	Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. 2012 , 142, 614-621	35
276	Connective Tissue Disease-associated Interstitial Lung Disease: A review. 2012 , 1, 224-232	74
275	Interstitial lung disease in connective tissue disorders. 2012 , 380, 689-98	247

274	Interstitial lung disease in the connective tissue diseases. 2012 , 33, 123-49		31
273	Therapeutic Evolution: A Professor's View. 2012 , 7-12		
272	Treatment of Interstitial Lung Disease. 2012 , 421-427		1
271	Immunomodulatory Therapies. 2012 , 577-589		
270	Sclérodémie systémique. 2012 , 7, 1-14		
269	N-TroBNP as biomarker in systemic sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 43, 292-303		8
268	Immunosuppressive therapy for autoimmune lung diseases. 2012 , 32, 633-69		10
267	Diffuse Lung Disease. 2012 ,		2
266	Highlights of the Brazilian Thoracic Association guidelines for interstitial lung diseases. 2012 , 38, 282-91		23
265	Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. 2012 , 6, 131-43		36
264	Molecular targets for therapy in systemic sclerosis. 2012 , 5, S19		12
263	Fibrose pulmonaire: dans quels cas et sur quels critères envisager une admission en réanimation ? 2013 , 22, 45-53		1
262	My approach to the treatment of scleroderma. 2013 , 88, 377-93		42
261	Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. <i>Respiratory Medicine</i> , 2013 , 107, 1079-86	4.6	42
260	Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. 2013 , 51, 69-75		22
259	Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. 2013 , 143, 814-824		195
258	Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. 2013 , 40, 640-6		250
257	Scleroderma therapy: clinical overview of current trends and future perspective. 2013 , 33, 1-18		12

256	Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. 2013 , 65, 2917-27		28
255	Can large simple trials help us understand when and how to use generic drugs for uncommon diseases?. 2013 , 40, 539-41		1
254	Scleroderma lung disease. 2013 , 22, 6-19		158
253	Treatment options in systemic sclerosis. 2013 , 1, 851-865		
252	Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point. 2013 , 3, 1139-1146		
251	Outcomes in systemic sclerosis-related lung disease after lung transplantation. 2013 , 95, 975-80		58
250	Interstitial lung diseases: respiratory review of 2013. <i>Tuberculosis and Respiratory Diseases</i> , 2013 , 75, 47-51	3.2	2
249	The lungs in connective tissue disease. 804-846		
248	Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. 2014 , 1,		34
247	Interstitial Lung Disease in Connective Tissue Disease. 2014 , 21, 282		
246	Biomarkers in connective tissue disease-associated interstitial lung disease. 2014 , 35, 181-200		42
245	Protocolo de indicaci3n y administraci3n de inmunosupresi3n y terapias biol3gicas en las enfermedades pulmonares intersticiales. 2014 , 11, 3830-3834		
244	Vasculitic Neuropathies and Neuropathies of Connective Tissue Diseases. 2014 , 733-785		3
243	The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope. <i>American Journal of the Medical Sciences</i> , 2014 , 347, 54-63	2.2	16
242	Current approach to connective tissue disease-associated interstitial lung disease. 2014 , 20, 449-56		20
241	Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease. 2014 , 40, 17-21		8
240	Interstitial lung disease in systemic sclerosis. 2014 , 35, 213-21		42
239	Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. 2014 , 17, 923-8		18

238	Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. 2014 , 66, 1967-78		120
237	Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. 2014 , 41, 418-20		19
236	Interstitial lung disease in systemic sclerosis. <i>Presse Medicale</i> , 2014 , 43, e329-43	2.2	31
235	Interstitial lung disease in connective tissue disease--mechanisms and management. 2014 , 10, 728-39		105
234	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , 2014 , 43, e345-63	2.2	34
233	From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015 , 29, 756-69	5.3	4
232	Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. 2015 , 9, 97-110		11
231	Interstitial Lung Disease and Rheumatoid Arthritis: A Review. 2015 , 24, 35-41		3
230	Biomarker discovery in systemic sclerosis: state of the art. 2015 , 47		2
229	Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 399-417	2.4	15
228	Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 439-57	2.4	35
227	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 372	5.7	61
226	Advances in pathogenesis and treatment of systemic sclerosis. 2015 , 15 Suppl 6, s58-63		36
225	Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. 2015 , 44, 437-44		40
224	Management of connective tissue disease-associated interstitial lung disease. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 279-94	2.4	12
223	Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. 2015 , 204, 408-22		12
222	Management of Scleroderma-Associated Pulmonary Involvement. 2015 , 1, 51-67		
221	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. 2015 , 54, 144-51		27

220	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. <i>Autoimmunity Reviews</i> , 2015 , 14, 575-8	13.6	25
219	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. 2015 , 42, 2168-71		99
218	Update on systemic sclerosis. 2015 , 15, 25		8
217	Systemic sclerosis. 2015 , 1, 15002		351
216	Interstitial lung disease in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 237-48	2.4	51
215	Esclerodermia sistêmica. 2015 , 48, 1-15		1
214	Interstitial lung disease in systemic sclerosis: where do we stand?. 2015 , 24, 411-9		61
213	Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015 , 7, 247-67	3.8	55
212	Old medications and new targeted therapies in systemic sclerosis. 2015 , 54, 1944-53		36
211	The Lung in Systemic Lupus Erythematosus. 2016 , 383-389		
210	Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 234-240	2.3	11
209	Current perspectives on the immunopathogenesis of systemic sclerosis. 2016 , 5, 21-35		44
208	Approche thérapeutique des pneumopathies interstitielles diffuses liées aux connectivites. <i>Revue Des Maladies Respiratoires Actualites</i> , 2016 , 8, 142-144	0	
207	Fibrose pulmonaire et auto-immunité des associations nuancées. <i>Revue Des Maladies Respiratoires Actualites</i> , 2016 , 8, 250-253	0	
206	Overlap-Syndrome. 2016 , 41, 76-80		
205	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. 2016 , 26, 523-34		12
204	Systemic sclerosis: The need for structured care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 3-21	5.3	9
203	Pneumopathie interstitielle et sclérodémie systémique. 2016 , 37, A16-A21		

202	Hematopoietic Cell Transplantation for Autoimmune Diseases. 2016 , 792-806		
201	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. 2016 , 4, 708-719	4	87
200	Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. 2016 , 13, 2045-2056		44
199	Therapeutic Approach to Adult Fibrotic Lung Diseases. 2016 , 150, 1371-1386		28
198	High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis. 2016 , 239, 297-305		23
197	Scleroderma Lung Study II-clarity or obfuscation?. 2016 , 4, 678-679		2
196	Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. 2016 , 68, 2361-71		17
195	Lung involvement in inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 870-888	5	3 22
194	Mycophenolate mofetil for scleroderma-related interstitial lung disease. 2016 , 4, e53		2
193	[Systemic sclerosis : What is currently available for treatment?]. 2016 , 57, 1155-1163		0
192	Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 123	5	7 31
191	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. 2016 , 12, 509-20		10
190	Strategy for treatment of fibrosis in systemic sclerosis: Present and future. 2016 , 43, 46-55		28
189	Advances in pathogenesis and treatment of systemic sclerosis. 2016 , 16, 55-60		32
188	Management of interstitial lung disease associated with connective tissue disease. 2016 , 352, h6819		137
187	Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. 2016 , 35, 2125-2130		26
186	Connective Tissue Diseases. 2016 , 1165-1187.e14		
185	Cyclophosphamide in dermatology. 2017 , 58, 5-17		32

184	Systemic sclerosis. 2017 , 390, 1685-1699	764
183	Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. 2017 , 46, 247-252	8
182	Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). 2017 , 23, 418-425	16
181	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. 2017 , 52, 1495-1503	62
180	Recent advances in connective tissue disease related interstitial lung disease. 2017 , 11, 591-603	14
179	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. 2017 , 69, 1451-1460	67
178	Pulmonary fibrosis, part II: state-of-the-art patient management. 2017 , 11, 361-376	6
177	Mycophenolate mofetil (MMF) for the treatment of connective tissue disease-associated interstitial lung disease (ILD). 2017 ,	78
176	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. 2017 , 151, 813-820	35
175	Update of EULAR recommendations for the treatment of systemic sclerosis. 2017 , 76, 1327-1339	497
174	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. 2017 , 56, v27-v32	20
173	Assessment of skin involvement in systemic sclerosis. 2017 , 56, v53-v66	32
172	How I treat patients with systemic sclerosis in clinical practice. <i>Autoimmunity Reviews</i> , 2017 , 16, 1024-1028	16
171	Treatment of Interstitial Lung Disease. 2017 , 375-383	
170	Immunomodulatory, Immunoablative, and Biologic Therapies. 2017 , 567-582	1
169	A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. 2017 , 46, 625-631	123
168	Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. 2017 , 52, 53-58	37
167	Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 72-83	2.3 22

166	Clinical Features and Treatment of Scleroderma. 2017 , 1424-1460.e5	2
165	Characteristics for Quality of Life during the Clinical Course of Interstitial Lung Disease. 2017 , 07,	
164	Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight. 2017 ,	0
163	Recent advances in managing systemic sclerosis. 2017 , 6, 88	3
162	Enfermedad pulmonar intersticial en pacientes con esclerosis sistémica. Revisión narrativa de la literatura. 2017 , 30, 276-286	
161	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. 2018 , 45, 633-691	16
160	Stem cell transplant in systemic sclerosis: An Indian experience. 2018 , 21, 859-865	5
159	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. 2018 , 14, 127-135	5
158	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. 2018 , 378, 35-47	266
157	Cyclophosphamide for connective tissue disease-associated interstitial lung disease. 2018 , 1, CD010908	39
156	Autologous Stem-Cell Transplantation for Severe Scleroderma. 2018 , 378, 1066-1067	11
155	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. 2018 , 70, 439-444	35
154	Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. 2018 , 56, 14-20	11
153	Chronic Diffuse Lung Diseases. 2018 , 227-298.e5	0
152	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. 2018 , 27,	50
151	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. 2018 , 15, 1286-1295	48
150	Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis. 2018 , 9, 2390	31
149	Connective Tissue Related Interstitial Lung Disease. 2018 , 7, 133-148	

148	Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. 2018 , 27,			32
147	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. 2018 , 24, 1961-1964			38
146	Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. 2018 , 2018, 6930297			22
145	Interstitial Lung Disease in the Connective Tissue Diseases. 2018 , 157-185			
144	Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. 2018 , 13, e0196048			23
143	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018 , 20, 17	5-7		60
142	Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. 2018 , 37, 3043-3050			5
141	Major lung complications of systemic sclerosis. 2018 , 14, 511-527			43
140	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. 2019 , 58, 567-579			35
139	The Fibrosis Burden of Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1200-1202		10.2	0
138	Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. 2019 , 40, 501-518			13
137	. 2019 , 40S, S20-S23			
136	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. 2019 , 46, 1006-1013			24
135	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. 2019 , 15, 1009-1017			23
134	Scleroderma-related interstitial lung disease: principles of management. 2019 , 13, 357-367			5
133	Interstitial lung disease associated with systemic sclerosis (SSc-ILD). <i>Respiratory Research</i> , 2019 , 20, 13	7-3		80
132	Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview. 2019 , 40, 208-226			10
131	Rituximab in connective tissue disease-associated interstitial lung disease. 2019 , 38, 2001-2009			21

130	Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization. 2019 , 56, 94-99	3
129	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. 2019 , 46, 1316-1325	18
128	Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management. 2019 , 6, 248	7
127	Application of stem cell transplantation in autoimmune diseases. 2019 , 26, 392-398	9
126	Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. 2019 , 11, 283-307	11
125	Management of systemic sclerosis-associated interstitial lung disease. 2019 , 31, 241-249	38
124	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. 2019 , 78, 122-130	88
123	Scope and Consistency of Outcomes Reported in Trials of Patients With Systemic Sclerosis. 2020 , 72, 1449-1458	4
122	Lung disease related to connective tissue diseases. 2020 , 265-319	
121	Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. 2020 , 13, 1203-1218	1
120	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease. 2020 , 99, 628-636	6
119	An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. 2020 , 21, 2041-2056	4
118	Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. 2020 , 198, 735-759	10
117	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. 2020 , 2, 362-370	9
116	Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience. 2021 , 133, 1070-1075	1
115	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. 2020 , 16, 547-560	2
114	Drugs in phase I and phase II clinical trials for systemic sclerosis. 2020 , 29, 349-362	7
113	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 61-71	2.3 26

112	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020 , 22, 56	5.7	6
111	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. 2020 , 9,		20
110	Systemic sclerosis-associated interstitial lung disease. 2020 , 8, 304-320		73
109	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. 2020 , 9,		33
108	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. 2020 , 72, 1350-1360		30
107	Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease. 2020 , 14, 1179548420913281		6
106	The lung in systemic lupus erythematosus. 2021 , 427-438		
105	A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. 2021 , 43, 65-86		7
104	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). 2021 , 80, 143-150		41
103	Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 117-122	2.3	1
102	Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. <i>Autoimmunity Reviews</i> , 2021 , 20, 102742	13.6	6
101	Hematopoietic stem cell transplantation in systemic sclerosis: Yes!! BUT. . . <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 44-49	2.3	1
100	Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases. 2021 , 10,		
99	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. 2021 , 7,		3
98	[Pulmonary manifestations in adult rheumatic diseases]. 2021 , 80, 13-32		
97	A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. 2021 , 10,		1
96	Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. 2021 , 66, 101987		4
95	Immunosuppression use in early systemic sclerosis may be increasing over time.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 33-41	2.3	

94	Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. 2021 , 3, 295-304		3
93	Natural variability in the disease course of SSc-ILD: implications for treatment. 2021 , 30,		7
92	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. 2021 , 14,		2
91	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. 2021 , 10,		5
90	Treatment for systemic sclerosis-associated interstitial lung disease. 2021 , 33, 240-248		8
89	C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. <i>Modern Rheumatology</i> , 2021 , 1-8	3-3	
88	Treatment of chronic fibrosing interstitial lung diseases. 2021 , 64, 277-285		
87	Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. 2021 , 40, 4071-4079		0
86	French recommendations for the management of systemic sclerosis. 2021 , 16, 322		3
85	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. 2021 ,		0
84	Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). 2021 , 10,		7
83	Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis. <i>Modern Rheumatology</i> , 2021 , 1-7	3-3	3
82	Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose. 2021 , 20, 209-212		
81	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-23	4-1	
80	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 757-780	2-4	0
79	Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101672	5-3	0
78	A Practical Approach to Connective Tissue Disease-Associated Lung Disease. 2012 , 217-237		4
77	Interstitial Lung Disease in Systemic Sclerosis. 2015 , 379-390		1

76	Interstitial Lung Disease in Undifferentiated Forms of Connective Tissue Disease. 2015 , 419-434		1
75	Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. <i>Modern Rheumatology</i> , 2011 , 21, 296-301	3.3	4
74	Chronic Diffuse Lung Diseases. 2011 , 213-276		3
73	Clinical Features and Treatment of Scleroderma. 2013 , 1366-1403.e4		7
72	Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients: Comparison With Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, 324-330	1.1	2
71	pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. <i>JCI Insight</i> , 2018 , 3,	9.9	24
70	Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 11-20	2.3	9
69	Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. <i>Open Rheumatology Journal</i> , 2011 , 5, 1-6	0.2	9
68	Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies. <i>Mediterranean Journal of Rheumatology</i> , 2018 , 29, 140-147	1.4	5
67	Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. <i>Mediterranean Journal of Rheumatology</i> , 2019 , 30, 33-37	1.4	10
66	Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2019 , 82, 285-297	3.3	9
65	Connective Tissue Disease and Vasculitis-Associated Interstitial Lung Disease. 2009 , 159-175		0
64	Systemic Scleroderma. 2010 , 1177-1186.e1		
63	Scleroderma Lung Disease. 2010 , 409-419		
62	A 28-Year-Old Woman with Early Diffuse Scleroderma and Shortness of Breath. 2011 , 115-125		
61	The lung in rheumatic disease. 2011 , 315-320.e2		
60	Immunosuppressives (chlorambucil, cyclosporine, cyclophosphamide [Cytosan], azathioprine [Imuran], mofetil, tacrolimus). 2011 , 529-538.e2		
59	Systemic Sclerosis: Severe Involvement of Internal Organs. 2011 , 67-88		

- 58 Pulmonary management of systemic sclerosis. **2011**, 1413-1425.e1
- 57 A 30-Year-Old Woman with Puffy Hands, Raynaud's Phenomenon, and Carpal Tunnel Syndrome. **2011**, 11-21
- 56 Connective Tissue Disease-Associated Interstitial Lung Disease. *Korean Journal of Medicine*, **2013**, 84, 498 0.5
- 55 Connective Tissue Disease. **2014**, 91-122
- 54 Predicting Lung Function Decline with Serum Pneumoproteins: A Case Control Study. *Open Journal of Rheumatology and Autoimmune Diseases*, **2014**, 04, 52-57 0.2
- 53 Respiratory Homeostatic Dysfunction, Lower Respiratory Tract Dysfunction. **2014**, 99-250
- 52 The lung in rheumatic disease. **2015**, 274-278
- 51 Scleroderma: Not an orphan disease any more. *World Journal of Rheumatology*, **2015**, 5, 131 0.5
- 50 Pulmonary management of systemic sclerosis. **2015**, 1200-1212
- 49 Immunosuppressives. **2015**, 459-467 1
- 48 A Case of Systemic Sclerosis with Interstitial Lung Disease Successfully Treated with Intravenous Cyclophosphamide Pulse Therapy and Oral Azathioprine. *Nishinohon Journal of Dermatology*, **2016**, 78, 356-361 0
- 47 Pulmonale Manifestationen rheumatologischer Erkrankungen. **2016**, 77-89
- 46 Rapid Diffuse Skin Disease with Progressive Joint Contractures. **2017**, 683-690
- 45 Juvenile Localized and Systemic Scleroderma. **2017**, 75-89 1
- 44 Juvenile Systemic Sclerosis. **2017**, 403-411
- 43 Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide. **2017**, 707-712
- 42 Markers of Heart, Lung and Dorsal Aorta Damage of Mother Rats and Their Neonates Post Therapeutic Treatment with Doxorubicin, Cisplatin and 5-Fluorouracil. *Chinese Medicine*, **2017**, 08, 82-99 0.7
- 41 Pulmonary involvement in systemic sclerosis. **2019**, 90-105

40 Interstitial pneumonia with autoimmune features. **2019**, 140-152

39 BOEHRINGER INGELHEIM - Fibroses pulmonaires : maladies pulmonaires ou maladies systémiques ?. *Revue Des Maladies Respiratoires Actualites*, **2020**, 12, S58-S63

38 Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. *Autoimmunity Reviews*, **2021**, 20, 102978

37 Treatment of systemic sclerosis. *Presse Medicale*, **2021**, 50, 104088

36 Compromiso intersticial pulmonar en la esclerosis sistémica. *Revista Colombiana De Reumatología*, **2020**, 27, 36-43

35 Interstitial lung involvement in systemic sclerosis. *Revista Colombiana De Reumatología (English Edition)*, **2020**, 27, 36-43

34 Current therapy of interstitial pneumonia associated with systemic scleroderma. *Nauchno-Prakticheskaya Revmatologiya*, **2020**, 58, 520-531

33 An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View. *Journal of Clinical and Aesthetic Dermatology*, **2012**, 5, 33-43

32 Treatment of early diffuse systemic sclerosis skin disease. *Clinical and Experimental Rheumatology*, **2013**, 31, 166-71

31 Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2021**, 38, e2021002

30 Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. *Journal of Scleroderma and Related Disorders*, **2020**, 5, 61-71

29 Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. *Respiratory Medicine*, **2021**, 191, 106689

28 Use of Mycophenolate Mofetil for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. *Modern Rheumatology*, **2021**,

27 Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?. *Therapeutic Advances in Musculoskeletal Disease*, **2021**, 13, 1759720X211059605

26 Choosing pharmacotherapy for ILD in patients with connective tissue disease.. *Breathe*, **2021**, 17, 210114.8

25 Systemic Sclerosis. **2022**, 107-135

24 Pulmonale Manifestationen rheumatologischer Erkrankungen. **2022**, 83-100

23 Systemic sclerosis in adults. Part II: Management and therapeutics.. *Journal of the American Academy of Dermatology*, **2022**,

22	Lung involvement in systemic sclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022 , 73-103	0.3	
21	Benefits and risks of Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.. <i>Modern Rheumatology</i> , 2022 ,	3.3	
20	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.. <i>Clinical Reviews in Allergy and Immunology</i> , 2022 , 1	12.3	1
19	Chronic Dyspnea with Raynaud's Phenomenon and Elevated ANA: A Diagnosis of Systemic Sclerosis Sine Scleroderma.. <i>American Journal of the Medical Sciences</i> , 2022 ,	2.2	
18	Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022 , 24,	5.7	2
17	Treatment approach to connective tissue disease-associated interstitial lung disease. <i>Current Opinion in Pharmacology</i> , 2022 , 65, 102245	5.1	1
16	Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2022 , 23,	7.3	1
15	New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. 2022 , 11, 4631		0
14	Epidemiology and Treatment of Systemic Sclerosis in Korea. 2022 , 29, 200-214		0
13	Immunomodulatory treatment of interstitial lung disease. 2022 , 16, 175346662211170		1
12	Die interstitielle Lungenerkrankung bei systemischer Sklerose. 2022 , 42, 330-336		0
11	Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study. 2022 , 58, 7-10		0
10	Esclerodermia sisthica: tratamiento. 2022 , 55, 1-11		0
9	Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease: An Observational Study. 2023 , 64, 263-268		0
8	Scleroderma Skin. 2023 , 49, 249-262		0
7	Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen. 2023 , 77, 94-119		1
6	Recent advances in the treatment of systemic sclerosis associated interstitial lung disease. 10,		0
5	Chronic diffuse lung diseases. 2024 , 231-302		0

- 4 Pharmacological management of systemic sclerosis associated interstitial lung disease. 1-10
- 3 Unclassifiable Interstitial Lung Disease. **2023**, 671-682
- 2 Systemic Sclerosis and the Lung. **2023**, 193-205
- 1 Interstitial pneumonia with autoimmune features: monocentric prospective study. **2023**, 95, 224-229